BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22654429)

  • 1. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.
    Choi HS; Chun HJ; Park SH; Keum B; Seo YS; Kim YS; Jeen YT; Um SH; Lee HS; Kim CD; Ryu HS
    World J Gastroenterol; 2012 May; 18(19):2377-82. PubMed ID: 22654429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.
    Chan CC; Chien NH; Lee CL; Yang YC; Hung CS; Tu TC; Wu CH
    BMC Gastroenterol; 2015 Dec; 15():170. PubMed ID: 26635102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy.
    Hassan C; De Francesco V; Zullo A; Scaccianoce G; Piglionica D; Ierardi E; Panella C; Morini S
    Aliment Pharmacol Ther; 2003 Sep; 18(6):641-6. PubMed ID: 12969091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study.
    Nasa M; Choksey A; Phadke A; Sawant P
    Indian J Gastroenterol; 2013 Nov; 32(6):392-6. PubMed ID: 24158898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
    De Francesco V; Zullo A; Hassan C; Della Valle N; Pietrini L; Minenna MF; Winn S; Monno R; Stoppino V; Morini S; Panella C; Ierardi E
    Dig Liver Dis; 2004 May; 36(5):322-6. PubMed ID: 15191200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
    Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
    Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure.
    Valooran GJ; Kate V; Jagdish S; Basu D
    Scand J Gastroenterol; 2011 Sep; 46(9):1045-50. PubMed ID: 21627398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.
    Park HG; Jung MK; Jung JT; Kwon JG; Kim EY; Seo HE; Lee JH; Yang CH; Kim ES; Cho KB; Park KS; Lee SH; Kim KO; Jeon SW
    Aliment Pharmacol Ther; 2012 Jan; 35(1):56-65. PubMed ID: 22066530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
    Lüth S; Teyssen S; Kölbel CB; Singer MV
    Z Gastroenterol; 2001 Apr; 39(4):279-81, 284-5. PubMed ID: 11367976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.
    Chung JW; Jung YK; Kim YJ; Kwon KA; Kim JH; Lee JJ; Lee SM; Hahm KB; Lee SM; Jeong JY; Yun SC
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1675-80. PubMed ID: 22849546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
    De Francesco V; Zullo A; Margiotta M; Marangi S; Burattini O; Berloco P; Russo F; Barone M; Di Leo A; Minenna MF; Stoppino V; Morini S; Panella C; Francavilla A; Ierardi E
    Aliment Pharmacol Ther; 2004 Feb; 19(4):407-14. PubMed ID: 14871280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.
    Scaccianoce G; Hassan C; Panarese A; Piglionica D; Morini S; Zullo A
    Can J Gastroenterol; 2006 Feb; 20(2):113-7. PubMed ID: 16482238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer].
    Boixeda de Miquel D
    Rev Esp Enferm Dig; 1997 Dec; 89(12):875-7. PubMed ID: 9494374
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
    Yang KC; Wang GM; Chen JH; Chen TJ; Lee SC
    J Formos Med Assoc; 2003 Dec; 102(12):857-62. PubMed ID: 14976565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
    Isomoto H; Furusu H; Ohnita K; Wen CY; Inoue K; Kohno S
    World J Gastroenterol; 2005 Mar; 11(11):1629-33. PubMed ID: 15786539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer].
    Gisbert JP; Mur M; Boixeda D; Ceña G; Martín de Argila C; Alvarez Baleriola I; Abraira V; García Plaza A
    Med Clin (Barc); 1997 Apr; 108(14):524-9. PubMed ID: 9190436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
    Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
    De Francesco V; Della Valle N; Stoppino V; Amoruso A; Muscatiello N; Panella C; Ierardi E
    Aliment Pharmacol Ther; 2004 May; 19(9):993-8. PubMed ID: 15113366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer.
    Romero-Gómez M; Martínez-Delgado C; Hergueta P; Navarro JM; Garrido-Serrano A; Santos O; Montojo C
    Aliment Pharmacol Ther; 2003 Nov; 18(10):1023-9. PubMed ID: 14616169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.